Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockadeJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62023-05-088OAAI
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without IpilimumabCLINICAL CANCER RESEARCHIF10.22019-04-0172OAAI